Annexon, Inc. (ANNX): Capital Expenditures
$137.0K
Year ended 2025-12-31
$185.0K
Trailing 12 months to 2026-06-30
-72.4%
3-year compound annual growth
-21.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $137.0K | +813.3% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $15.0K | -92.2% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $193.0K | -97.0% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $6.53M | +294.6% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $1.65M | +256.5% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $464.0K | +73.8% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $267.0K | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $137.0K | +813.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $231.0K | -55.1% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $11.0K | n/a |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $141.0K | -78.8% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗